ArticleBMB reports2019

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.

Yujin Jin et al.PubMed ↗Full text ↗

No numbers read from the abstract.